Search results for "middle"

showing 10 items of 15335 documents

In Vivo Functional Evaluation of Tissue-Engineered Vascular Grafts Fabricated Using Human Adipose-Derived Stem Cells from High Cardiovascular Risk Po…

2016

Many preclinical evaluations of autologous small-diameter tissue-engineered vascular grafts (TEVGs) utilize cells from healthy humans or animals. However, these models hold minimal relevance for clinical translation, as the main targeted demographic is patients at high cardiovascular risk such as individuals with diabetes mellitus or the elderly. Stem cells such as adipose-derived mesenchymal stem cells (AD-MSCs) represent a clinically ideal cell type for TEVGs, as these can be easily and plentifully harvested and offer regenerative potential. To understand whether AD-MSCs sourced from diabetic and elderly donors are as effective as those from young nondiabetics (i.e., healthy) in the conte…

0301 basic medicineAdultPathologymedicine.medical_specialtyCell typeBiomedical EngineeringAdipose tissueContext (language use)Bioengineering030204 cardiovascular system & hematologyBiochemistryBiomaterials03 medical and health sciences0302 clinical medicineTissue engineeringBlood vessel prosthesisRisk FactorsDiabetes mellitusmedicineAnimalsHumansAgedBioprosthesisTissue Engineeringbusiness.industryMesenchymal stem cellMesenchymal Stem CellsOriginal ArticlesMiddle Agedmedicine.diseaseBiomaterialBlood Vessel ProsthesisRats030104 developmental biologyAdipose TissueCardiovascular DiseasesRats Inbred LewFemaleStem cellbusiness
researchProduct

Characterization of endometriosis-associated immune cell infiltrates (EMaICI)

2016

Objective: To identify and characterize endometriosis-associated immune cell infiltrates (EMaICI). Furthermore, to define occurrence and size of EMaICI in various types of endometriosis. Methods: Immune cells were characterized in samples of 60 premenopausal women with histological proven endometriosis. Therefore, immunohistochemical staining with monoclonal antibodies for CD3, CD4, CD8, CD45RO, CD25, CD56, CD68, and CD20 on sections of paraffin-embedded endometriotic tissue was performed. Results: EMaICI were observed in all the types of endometriosis, and characterized as T lymphocytes (CD3+), helper T lymphocytes (CD4+), cytotoxic T lymphocytes (CD8+), antigen-experienced T lymphocytes”m…

0301 basic medicineAdultPathologymedicine.medical_specialtyCellEndometriosisEndometriosisImmune cell defectChronic inflammatory disease03 medical and health sciences0302 clinical medicineImmune systemImmune cell infiltratemedicineHumansLymphocytesOvarian DiseasesEndometriosi030219 obstetrics & reproductive medicinebusiness.industryMacrophagesMedicine (all)Chronic inflammatory diseaseObstetrics and GynecologyGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryHuman genetics030104 developmental biologymedicine.anatomical_structureImmunologyFemalebusiness
researchProduct

Solitary Fibrous Tumor of the Vulva: Report of 2 Cases, Including a De Novo Dedifferentiated Solitary Fibrous Tumor Diagnosed After Molecular Demonst…

2018

Solitary fibrous tumor (SFT) is a neoplasm of fibroblastic lineage that has been documented in almost every anatomic location. Vulval SFT is very rare with only 10 cases reported to date. We present 2 additional SFTs located in the vulva, in adult women of 59 and 25 yr of age. The first showed a classic morphology and immunophenotype with uniform and strong STAT6 nuclear expression. The other one was a spindle-cell de novo dedifferentiated SFT with heterogeneous nuclear and cytoplasmic STAT6 staining, which could only be correctly diagnosed after molecular analysis with demonstration of a NAB2-STAT6 gene fusion. This genetic aberration is considered to represent the major pathogenic driver …

0301 basic medicineAdultPathologymedicine.medical_specialtySolitary fibrous tumorLineage (genetic)Oncogene Proteins FusionBiologyPathology and Forensic MedicineVulvaVulva03 medical and health sciences0302 clinical medicineImmunophenotypingmedicineNeoplasmHumansOncogene FusionDedifferentiated Solitary Fibrous TumorVulvar NeoplasmsObstetrics and GynecologyMiddle Agedmedicine.diseaseRepressor Proteins030104 developmental biologymedicine.anatomical_structure030220 oncology & carcinogenesisSolitary Fibrous TumorsOncogene FusionFemaleDifferential diagnosisSTAT6 Transcription FactorInternational journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
researchProduct

Roux-en-Y Gastric Bypass as an Effective Bariatric Revisional Surgery after Restrictive Procedures

2020

<b><i>Introduction:</i></b> Revisional surgery must be considered when insufficient weight loss is attained or weight is subsequently regained. This study aimed to investigate the value of Roux-en-Y gastric bypass (RYGB) as a revisional procedure after restrictive surgery. <b><i>Materials and Methods:</i></b> An observational, retrospective study including patients initially operated on for morbid obesity with restrictive techniques (vertical-banded gastroplasty [VBG], adjustable gastric band [AGB], and sleeve gastrectomy) and reoperated with RYGB in our centre between December 1994 and January 2019. Demographic and anthropometric data, associ…

0301 basic medicineAdultReoperationSleeve gastrectomymedicine.medical_specialtyHealth (social science)Gastroplastymedicine.medical_treatmentGastric bypassGastric BypassPulmonary diseaseBariatric Surgerylcsh:TX341-641030209 endocrinology & metabolismComorbidity03 medical and health sciences0302 clinical medicineWeight lossPhysiology (medical)Weight LossmedicineHumansAdjustable gastric bandIntraoperative Complicationslcsh:RC620-627Retrospective Studies030109 nutrition & dieteticsbusiness.industryMortality rateRetrospective cohort studyLength of StayMiddle AgedRoux-en-Y anastomosisSurgeryObesity Morbidlcsh:Nutritional diseases. Deficiency diseasesconversion surgeryinsufficient weight lossmedicine.symptombusinesslcsh:Nutrition. Foods and food supplyResearch Article
researchProduct

Polymorphisms in genes involved in T-cell co-stimulation are associated with blood pressure in women.

2019

In recent years, conclusive data have emerged on a relationship between immune system, especially the T-cell, and blood pressure (BP). The objective of the present study was to determine the association between BP and four polymorphisms in CD80, CD86, CD28 and CTLA4 genes that code for key proteins in the T-cell co-stimulation process, in a female cohort. To that end, an association study in a cohort of 934 women over 40 years old from two hospitals was done. Raw data showed a significant association between the SNP rs1129055 of CD86 gene and BP. Analyzing this association against inheritance patterns, higher SBP (p  0.000) and DBP (p = 0.005) values were observed in AA than in GG/GA genoty…

0301 basic medicineAdultT cellT-LymphocytesPhysiologychemical and pharmacologic phenomenaBlood PressureBiologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineImmune systemCD28 AntigensGeneticsmedicineInheritance PatternsSNPHumansCTLA-4 AntigenGenetic Predisposition to DiseaseGeneCD86hemic and immune systemsGeneral MedicineMiddle Aged030104 developmental biologyBlood pressuremedicine.anatomical_structure030220 oncology & carcinogenesisCohortB7-1 AntigenFemaleB7-2 AntigenGene
researchProduct

Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.

2021

Objective To compare ovarian response and reproductive outcomes in oocyte donors undergoing pituitary suppression with medroxyprogesterone acetate (MPA) versus those undergoing conventional treatment with a gonadotropin-releasing hormone (GnRH) antagonist. Design A prospective, randomized, controlled trial of cycles was conducted from October 2017 to June 2019 to evaluate ovarian response in terms of the number of oocytes. The reproductive outcomes of the recipients were retrospectively analyzed later. Setting A university-affiliated private in vitro fertilization center. Patient(s) We randomly divided 318 donors into 2 groups in a 1:1 ratio. The oocytes obtained were assigned to 364 recipi…

0301 basic medicineAdultmedicine.drug_classmedia_common.quotation_subjectMedroxyprogesterone AcetateGonadotropin-releasing hormone antagonistAndrologyGonadotropin-Releasing Hormone03 medical and health sciences0302 clinical medicineOvulation InductionPregnancyFollicular phasemedicineMedroxyprogesterone acetateHumansProspective StudiesGanirelixOvulationmedia_common030219 obstetrics & reproductive medicineEstradiolOocyte Donationbusiness.industryAntagonistObstetrics and GynecologyLuteinizing HormoneMiddle AgedFollicular fluid030104 developmental biologyReproductive MedicineFemaleLuteinizing hormonebusinessmedicine.drugFertility and sterility
researchProduct

Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort.

2018

Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter retrospective database, we studied the effectiveness of HMAs in RR-AML and evaluated for predictors of response and overall survival (OS). A total of 655 patients from 12 centers received azacitidine (57%) or decitabine (43%), including 290 refractory (44%) and 365 relapsed (56%) patients. Median age at diagnosis was 65 years. Best response to HMAs was complete remission (CR; 11%) or CR with incomplete count recovery (CRi; 5.3%). …

0301 basic medicineAdultmedicine.medical_specialtyAntimetabolites AntineoplasticMyeloidAdolescentDatabases FactualAzacitidineDecitabineSalvage therapyDecitabineCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicineRefractoryInternal medicinehemic and lymphatic diseasesmedicineHumansSurvival analysisAgedRetrospective StudiesAged 80 and overSalvage TherapyMyeloid Neoplasiabusiness.industryRemission InductionRetrospective cohort studyHematologyDNA MethylationMiddle Agedmedicine.diseasePrognosisSurvival AnalysisLeukemiaLeukemia Myeloid Acute030104 developmental biologymedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisAdolescent; Adult; Aged; Aged 80 and over; Antimetabolites Antineoplastic; Cohort Studies; DNA Methylation; Databases Factual; Decitabine; Humans; Leukemia Myeloid Acute; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Young Adultbusinessmedicine.drug
researchProduct

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer…

2016

Summary Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel after surgery. Here, we report 5-year progression-free survival, disease-free survival, and safety. Methods In this multicentre, open-label, phase 2 randomised trial in hospitals and medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage HER2-positive breast cancer were randomly assigned (1:1:1:1) to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus do…

0301 basic medicineAdultmedicine.medical_specialtyTime FactorsAdolescentReceptor ErbB-2PopulationAntibodies Monoclonal HumanizedGastroenterologyGroup B03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overeducation.field_of_studybusiness.industryMiddle AgedTrastuzumabmedicine.diseasePrognosisNeoadjuvant TherapySurgerySurvival Rate030104 developmental biologyOncologyDocetaxelTolerabilityChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleInflammatory Breast NeoplasmsPertuzumabNeoplasm Recurrence LocalbusinessFebrile neutropeniamedicine.drugEpirubicinFollow-Up StudiesThe Lancet. Oncology
researchProduct

Observational prospective study on Lactobacillus plantarum P 17630 in the prevention of vaginal infections, during and after systemic antibiotic ther…

2018

We performed a prospective cohort parallel observational study on the use of Lactobacillus plantarum P 17630 in the prevention of vaginal infections. Eligible were women with a diagnosis of bacterial vaginosis (15 days) and documented history of recurrent vaginal infections; and/or cystitis (15 days); and/or treatment with antibiotics for bacterial respiratory tract infections during the week before the study entry. Study subjects were prescribed Lactobacillus plantarum P 17630  100.000.000 UFC one vaginal capsule per day for 6 days, then a capsule per week for 16 weeks. Eligible subjects were enrolled in two parallel cohorts: 85 women using (group A) and 39 not using (group B) Lactobacillu…

0301 basic medicineAdultmedicine.medical_specialtymedicine.drug_class030106 microbiologyAntibioticsPopulationGroup B03 medical and health sciences0302 clinical medicineInternal medicineCystitismedicineSecondary PreventionHumansProspective StudiesProspective cohort studyeducationVaginitisRespiratory Tract Infectionseducation.field_of_studybiologyGenitourinary systembusiness.industryProbioticsPreventionfood and beveragesObstetrics and GynecologyMiddle Agedmedicine.diseasebiology.organism_classification030205 complementary & alternative medicineAnti-Bacterial AgentsObservational studyFemaleBacterial vaginosisbusinessbacterial vaginosis; Lactobacillus plantarum; Prevention; Adult; Anti-Bacterial Agents; Cystitis; Female; Humans; Middle Aged; Probiotics; Prospective Studies; Respiratory Tract Infections; Secondary Prevention; Vaginitis; Lactobacillus plantarum; Obstetrics and GynecologyLactobacillus plantarumbacterial vaginosis; Lactobacillus plantarum; Preventionbacterial vaginosisLactobacillus plantarum
researchProduct

The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular…

2015

Summary In this work, we aimed to evaluate the levels of ferritin enriched in H subunits (H-ferritin) and ferritin enriched in L subunits (L-ferritin) and the cells expressing these two molecules in the lymph node (LN) biopsies obtained from adult-onset Still's disease (AOSD) patients, and the possible correlation among these data and the severity of the disease. Ten patients with AOSD underwent LN biopsy. All the samples were stained by immunofluorescence. A statistical analysis was performed to estimate the possible correlation among both H-ferritin and L-ferritin tissue expression and the clinical picture of the disease. Furthermore, the same analysis was performed to evaluate the possib…

0301 basic medicineAdult-OnsetMalePathologyMacrophageApoferritinAdult-onset Still's disease; H-ferritin; Hyperferritinaemic syndrome; Macrophage; Adult; Aged; Antigens CD; Antigens Differentiation Myelomonocytic; Apoferritins; Biopsy; Female; Ferritins; Fluorescent Antibody Technique; Humans; Lymph Nodes; Macrophages; Male; Middle Aged; Still's Disease Adult-Onset; Immunology; Immunology and AllergyH-ferritinBiopsyFluorescent Antibody TechniquePathogenesis0302 clinical medicineMacrophageImmunology and AllergyLymph nodemedicine.diagnostic_testCD68Lymph NodeMiddle AgedCDmedicine.anatomical_structureAntigenDifferentiationFemaleLymphHyperferritinaemic syndromeStill's Disease Adult-OnsetHumanAdultmedicine.medical_specialtyImmunologyAntigens Differentiation MyelomonocyticBiologyImmunofluorescenceAdult-onset Still's disease03 medical and health sciencesAntigens CDBiopsymedicineHumansAntigensAged030203 arthritis & rheumatologyFerritinMacrophagesOriginal ArticlesMyelomonocyticStill's DiseaseFerritinSettore MED/16 - Reumatologia030104 developmental biologyImmunologyApoferritinsFerritinsbiology.proteinLymph Nodes
researchProduct